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Glomerular cellsPrior studies have shown that pan-HDAC inhibition can decrease disease in lupus mice; however, the
mechanisms(s) remain to be elucidated. MRL/MpJ-Faslpr (MRL/lpr) mice develop a lupus-like disease character-
ized by anti-dsDNAproduction, lymphoproliferation, and immune complex-mediated glomerulonephritis. Early-
and late-disease (12 and 20 weeks-of-age respectively) female MRL/lpr mice were compared to age-matched,
healthy C57BL/6 mice for HDAC expression and activity in bone marrow (BM) B cells, splenic B and T cells, and
glomerular cells. We found that HDAC6was signiﬁcantly overexpressed in B cells, splenic T cells and glomerular
cells, whereas HDAC9 expression was signiﬁcantly increased in splenic T cells, BM B cells and glomerular cells.
Due to the overexpression of HDAC6, we tested whether treatment with a selective HDAC6 inhibitor (ACY-
738) or a pan-HDAC inhibitor (TsA) would decrease HDAC activity. ACY-738 signiﬁcantly reduced cytoplasmic
HDAC activity whereas TsA signiﬁcantly decreased both nuclear and cytoplasmic HDAC activity. In vitro studies
inmesangial cells showed that ACY-738 increasedα-tubulin and Hsp90 acetylation resulting in decreased nucle-
ar activation of NF-κB. Treatment of pre-B cells with ACY-738 decreased the Bcl-2:Bax ratio leading to a pro-
apoptotic environment. These results suggest that increased HDAC6 expression and activity contribute to SLE
pathogenesis, and isoform-selective HDAC inhibitors may prove beneﬁcial in the treatment of SLE by acetylating
key signaling and transcription factors in inﬂammation and cell activation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a systemic autoimmune
disease characterized by the activation of autoreactive T and B cells
[1–3]. During SLE, pathogenic autoantibodies directed against nuclear
components, including nucleic acids and histones, are produced con-
tributing to multiorgan inﬂammation and tissue damage [4]. Studies
have shown a number of abnormalities in various stages of B cell devel-
opment in SLE patients including pre-immune B cell maturation, nega-
tive selection, receptor editing, and somatic hypermutation [5].
Furthermore, when autoreactive B cells encounter a self-antigen (Ag),
they form immune complexes (ICs) which become lodged in glomeru-
lar capillaries resulting in glomerulonephritis [6]. Aberrant T cell devel-
opment is also thought to contribute to disease in SLE patients.
Alterations in the balance and functions of T cell subsets in human SLECollege of VeterinaryMedicine,
s.
. This is an open access article underpatients and murine models include: decreased number and function
of regulatory T (Treg) cells, elevated Th1 and Th2 cytokines, and in-
creased numbers of Il-17-producing Th17 cells, which contribute to in-
ﬂammation [7,8].
Histone deacetylases (HDACs) catalyze the removal of acetyl groups
on both histone and non-histone proteins resulting in altered protein
stability and function [9,10]. HDACs have been shown to play a role in
the regulation of a number of proteins involved with cell cycle, motility,
immunity, inﬂammation, and apoptosis [11]. HDACs can be grouped
into four classes: class I, II, III, and IV. Class I HDACs (HDACs 1, 2, 3,
and 8) have ubiquitous tissue expression and are involvedwith cell sur-
vival and proliferation. HDACS 1, 2, and 3 are found solely in the nucle-
us; however, HDAC8 can be found in either thenucleus or the cytoplasm
[12]. Class II HDACs can be further subdivided into class IIa (HDACs 4, 5,
7, and 9) and class IIb (HDACs 6 and 10). Class IIa HDACs are able to
shuttle back and forth between the nucleus and the cytoplasm,whereas
class IIb HDACs are primarily cytosolic [9]. HDAC11 is the sole member
of class IV and can be found in either the nucleus or the cytoplasm, but
has a tendency to co-localizewith HDAC6 in the cytoplasm [12]. Studies
suggest that class II HDACs may be preferable targets for treatingthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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inhibiting class I HDACs has shown someefﬁcacy in the treatment of au-
toimmune disease, they have also been associated with cytotoxicity fol-
lowing long-term treatment [16,17]. For these reasons, we have focused
this study on the expression of class II HDACs and the role theymay play
in SLE pathogenesis.
Class IIa HDACs (4, 5, 7, and 9) are highly expressed in the heart,
brain, and smooth muscle [12]. Mice lacking HDAC4 are viable, but
have signiﬁcant defects including chondrocyte hypertrophy and prema-
ture ectopic ossiﬁcation [18]. Knockdown of HDAC5 in mice results in
signiﬁcant heart problems including myocardial hypertrophy and an
abnormal cardiac stress response [19]. Germline deletion of HDAC7 in
mice has proven to be embryonic lethal due to its role in endothelial
cell–cell adhesion [20]. HDAC9 overexpression is believed to contribute
to SLE pathogenesis. HDAC9 deﬁcient MRL/lpr mice have decreased
levels of autoantibody production, inﬂammatory cytokine production,
and glomerulonephritis coupled with prolonged survival [21]. T cells
fromboth SLE patients and SLEmurinemodels have been demonstrated
to overexpress HDAC9 [21]. Furthermore, inhibition of HDAC9 results in
increased Treg activation and suppressive function [13]. Due to the sig-
niﬁcant defects associatedwith class IIaHDACknockoutmice, inhibition
of these HDACs for the treatment of disease may produce a number of
adverse side effects.
Class IIb HDACs (HDAC6 andHDAC10) are found primarily in the cy-
toplasm. HDAC6 has been demonstrated to deacetylate a number of
proteins with speciﬁcity for α-tubulin and Hsp90 [22,23]. HDAC6 has
increased tissue expression in the kidneys, liver, heart, and pancreas
[12]. HDAC6-deﬁcient mice are viable with no signiﬁcant defects [22].
Mice lacking HDAC6 and those treated with HDAC6 siRNA have
hyperacetylated α-tubulin and Hsp90 [15,24]. Hyperacetylation of
Hsp90 has been shown to decrease Hsp90 function [22,24,25]. The
role of HDAC10 in autoimmune disease remains undetermined.
Due to the ubiquitous nature of class I HDACs, inhibition not only
alters autoimmune associated pathways, but also disrupts normal
physiological functions [12]. For this reason, pan-HDAC inhibitors
and class I selective HDAC inhibitors tend to be cytotoxic, and there-
fore the development of isoform-selective HDAC inhibitors for the
treatment of chronic diseases including SLE is warranted. The class I
and II HDACi, SAHA, has been approved by the FDA for the treatment
of cutaneous T cell lymphoma [26]. However, we have previously
published that while long-term treatment with SAHA can reduce
disease in lupus-prone mice, its long-term use may have deleterious
effects [16].
Due to their suggested role in autoimmune disease, we sought to de-
termine the mRNA expression level of class IIb HDACs (HDAC 6 and 10)
and one class IIa HDAC (HDAC9) in immune-associated tissues from
lupus-pronemice. Next, we investigatedwhether HDAC activitywas in-
creased during SLE disease and if treatment with a selective HDAC6i
would decrease HDAC activity in vitro and the mechanism(s) through
which the HDAC6i exerts its inhibitory effect.
2. Methods
2.1. Mice
Female MRL/MpJ-Faslpr (MRL/lpr) and C57BL/6 mice were obtained
from Jackson Laboratories (Bar Harbor, ME, USA) and housed in the an-
imal facility at the Virginia-Maryland Regional College of Veterinary
Medicine (VMRCVM, Blacksburg, VA, USA). All micewere used in accor-
dancewith the Institutional Animal Care and Use Committee of Virginia
Tech.
2.2. Isolation of BM B cells
BM cells were harvested from the tibias and femurs of MRL/lpr mice
and age-matched C57BL/6 mice following euthanization. Brieﬂy, BMcells were ﬂushed in PBS with 1% BSA followed by RBC lysis by ammo-
nium chloride potassium (ACK) lysing solution. B cells were isolated
using the Dynal Mouse B Cell Negative Isolation Kit according to the
manufacturer's protocol (Invitrogen, Life Technologies, Grand Island,
NY, USA). Cells were resuspended in RNAlater (Qiagen, Valencia, CA,
USA) and stored at−20 °C until RNA isolation or used for cytoplasmic
and nuclear extractions.
2.3. Splenocyte isolation
A single-cell suspension was obtained from the spleens of MRL/lpr
mice and age-matched C57BL/6 mice following euthanization. Brieﬂy,
the spleenwas removed from eachmouse and dissociated across a ster-
ile wire mesh in a petri dish containing ice-cold PBS with 1% BSA. RBCs
were lysed using RBC lysis buffer and cells were pelleted and washed
with PBS. B cells were isolated using the Dynal Mouse B Cell Negative
Isolation Kit according to the manufacturer's protocol (Invitrogen, Life
Technologies). Naïve T and Treg cellswere isolated using the appropriate
isolation kit according to the manufacturer's protocol (Miltenyi Biotec,
Auburn, CA, USA). Cells were resuspended in RNAlater (Qiagen,
Valencia, CA, USA) and stored at −20 °C until RNA isolation or used
for cytoplasmic and nuclear extractions.
2.4. Isolation of glomerular cells
Following euthanization, the glomeruli were removed fromMRL/lpr
mice andwere pooled for glomerular cell isolation aswe have previous-
ly published [27]. This procedure was repeated three separate times for
each group. Brieﬂy, the cortical tissue was isolated from one kidney of
each mouse and pooled by group. Next, cortical tissue was pressed
through grading sieves (180, 150, and 75 μm mesh) and resuspended
in 750 U/mL Worthington type I collagenase at 37 °C for 20 min.
Glomerular cells were pelleted, resuspended in RNAlater (Qiagen,
Valencia, CA, USA), and stored at −20 °C until RNA isolation or used
for cytoplasmic and nuclear extractions.
2.5. Isolation of RNA
RNA was isolated using the mirVana miRNA isolation kit according
to the manufacturer's protocol (Applied Biosystems, Carlsbad, CA,
USA). The eluates were quantiﬁed on a spectrophotometer (Nanodrop,
Thermo Scientiﬁc, Waltham, MA, USA). An aliquot was taken and
diluted to 1 ng/μL for real-time RT-PCR. The eluted RNA was stored
at−80 °C.
2.6. Real-time RT-PCR
HDAC6, HDAC9, and HDAC10 mRNA expression were measured
using TaqMan Gene Expression assays (Applied Biosystems, Carlsbad,
CA, USA). The ΔCT was calculated using the endogenous control
GAPDH, and then the ΔΔCT was determined by calculating the fold
change in expression between MRL/lpr mice and age-matched control
mice. All samples were run in triplicate.
2.7. Nuclear and cytoplasmic extraction
Isolated BM B cells, splenic B and T cells, and glomerular cells were
lysed, then cytoplasmic and nuclear protein fractions were extracted
using NE-PER nuclear and cytoplasmic extraction reagents (Thermo
Scientiﬁc) according to the manufacturer's protocol.
2.8. Cell culture
A mouse mesangial cell line (MES 13) transgenic for SV40 was cul-
tured in 75-mm2 culture ﬂasks at 37 °C in 5% CO2 in DMEM and Ham's
F12 medium with 14 mM HEPES (3:1), supplemented with 10% FBS
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LPS (1 μg/mL) (Sigma-Aldrich, St. Louis, MO, USA) and IFN-γ (100
ng/mL) (Cedarlane Laboratories Limited, Burlington, NC, USA) were
used to induce immune stimulation in mesangial cells. MES 13 cells
were treated with varying concentrations of ACY-738 (1, 2, 5, 10 or
100 nM) for 24 h in order to determine the level of acetylated H3 or
α-tubulin. In order to determine the level of Hsp90 acetylation and
iNOS protein, MES 13 cells were treated with varying concentrations
of ACY-738 (0.5, 1, or 5 nM) for 2 h followed by 24 h of stimulation
with LPS/IFN-γ. MES 13 cells were treated with ACY-738 (5 nM) for
2 h and stimulated with LPS/IFN-γ for 15, 30, or 60 mins for nuclear ex-
traction in order to determine the effect of HDAC6 inhibition on NF-κB.2.9. Immunoprecipitation
To determine the level of HDAC6 activity in BM, splenic, and glomer-
ular cells fromMRL/lpr and C57BL/6mice, HDAC6proteinwas immuno-
precipitated as previously published [28]. The immunoprecipitated
proteinwas normalized using the Bradford protein assay then subjected
to the HDAC activity assay.2.10. Western blot analysis
In order to determine the speciﬁcity of ACY-738 for HDAC6,
α-tubulin and histone H3 acetylation was determined using Western
blot analysis. Brieﬂy, cells were lysed and the Bradford protein assay
was used to normalize protein levels. The cell pellet was resuspended
1:1 in cell lysis buffer and Laemmli buffer. The samples were heated
to 95 °C for 5 min and then loaded onto a 15% SDS-PAGE gel. The
proteins were transferred to a polyvinylidene diﬂuoride (PVDF) mem-
brane and incubated with antibodies against acetylated lysines,
acetylated α-tubulin, acetylated histone H3, histone H4, iNOS, NF-κB,
or β-actin (Cell Signaling, Boston, MA, USA). All experiments were run
in triplicate.2.11. HDAC activity analysis
The HDAC activity colorimetric assay kit (Bio Vision, USA) was used
according to the manufacturer's protocol to determine the level of
HDAC activity in freshly isolated B, T, and glomerular cells. Brieﬂy,
nuclear and cytoplasmic cell lysates were incubatedwith the HDAC col-
orimetric substrate followed by treatment with the lysine developer.
The plate was read at 405 nm on a Spectramax 340PC microplate
spectrophotometer.2.12. Pre-B colony formation assay
A single-cell suspension of BM cells was obtained from 8-week-old
MRL/lpr mice as described earlier. Isolated BM cells were mixed
with Methocult M3630 medium (StemCell Technologies, Vancouver,
Canada) in a 1:10 (v/v) ratio according to the manufacturer's protocol.
Cells were plated in triplicate in pre-tested culture dishes and incubated
in a humidiﬁed incubator at 37 °C and 5% CO2. Colonies were counted
and then collected for Western blot analysis after 8 days of culture.2.13. Statistical analysis
Statistical analysis was performed using Student's unpaired t-test
(two-tailed). When three or more independent groups were compared
a one-way ANOVAwas used followed by Tukey's post-test. P values less
than 0.05 were considered statistically signiﬁcant.3. Results
3.1. HDAC expression is increased in diseased MRL/lpr mice
FemaleMRL/lprmice develop an autoimmune inﬂammatory disease
that reﬂects lupus pathologies including proteinuria, autoantibody pro-
duction, and glomerulonephritis by 18 weeks-of-age [29]. On the other
hand, C57BL/6 mice did not exhibit proteinuria, anti-dsDNA or glomer-
ulonephritis regardless of age. In prior studies, we have shown that pan-
HDAC inhibitors decrease disease pathogenesis in lupus mice [28]. To
explore further the role of HDACs in lupus, wemeasuredmRNA expres-
sion levels ofHDAC6, 9, and 10 in lupusmice at 12 (early disease) and 20
weeks-of-age (late disease) and compared their expression levels to
age-matched non-lupus C57BL/6 mice (Fig. 1). We chose two class IIb
members, HDAC6 and 10, because they may serve as potential thera-
peutic targets for the treatment of SLE due to their regulation of
Hsp90 [12,15]. Increased Hsp90 levels during SLE have been associated
with an increase in IL-6, B cell activation and autoantibody production
[30]. We also chose HDAC9, a class IIa HDAC, as it has previously been
shown to play an important role in SLE pathogenesis due to its regula-
tion of Treg cells and Hsp90 acetylation [23,31,32]. Relative mRNA ex-
pression levels of the class IIb HDACs 6 and 10 and class IIa HDAC9
were determined using real-time RT-PCR. B cells isolated from the BM
of 12- and 20-week-old MRL/lpr mice had signiﬁcantly higher mRNA
expression of HDACs 6 and 9, and decreased HDAC10 when compared
to age-matched C57BL/6 mice (Fig. 1A). Expression of HDACs 6 and 10
were increased in splenic B cells from diseased MRL/lpr mice; however,
there were no signiﬁcant differences in HDAC9 expression levels be-
tween MRL/lpr mice in an early or late disease state (Fig. 1B).
Next we examined the level of HDAC expression in splenic T cells as
naïve CD4+ T cell differentiation has been shown to be dysregulated
during SLE [33]. SLE patients andmurinemodels have an imbalance be-
tween the Th1 and Th2 phenotypes aswell as an increase in the number
of Th17 cells and a decrease in Treg cell function [8,34,35]. In T cells iso-
lated from the spleens of MRL/lpr mice, expression of HDACs 6 and 9
were signiﬁcantly increased compared to age-matched controlmice. In-
terestingly HDAC10 was signiﬁcantly decreased in the MRL/lpr mice
compared to controls (Fig. 1C).
The glomerulus is a capillary tuft at the beginning of the nephron
that functions to ﬁlter blood. Proper glomerular ﬁltration is maintained
by the glomerular basement membrane through the interaction of
podocytes, endothelial cells, andmesangial cells. During SLE, circulating
ICs become lodged in the glomeruli resulting in inﬂammation and if
unresolved, can result in renal failure. Therefore, we also examined
HDAC expression in glomerular cells. We found that glomerular cells
from MRL/lpr mice had signiﬁcantly higher HDAC6 and 9 expression;
however, there was no signiﬁcant difference in HDAC10 expression
compared to age-matched control mice (Fig. 1D).
3.2. Nuclear and cytoplasmic HDAC activity is increased in diseased
lupus-prone mice
Speciﬁc HDAC isoforms can be found alone in either the nucleus or
cytoplasm, or in both the nucleus and the cytoplasm. The class IIb
HDACs (HDAC6 and HDAC10) are found primarily in the cytoplasm,
whereas HDAC9 shuttles between the nucleus and the cytoplasm
based on HDAC activity. We sought to determine whether or not there
was an increase in HDAC activity in immune-associated tissues as well
as whether activity was primarily cytoplasmic or nuclear. An HDAC ac-
tivity assaywas used in order to determine the level of HDAC activity in
B, T, and glomerular cells.We found that HDAC activitywas signiﬁcantly
greater in BM B cells, splenic B and T cells, and glomerular cells isolated
fromMRL/lpr mice compared to age-matched C57BL/6 mice (Fig. 2). In
the BM, we found a signiﬁcant elevation in the cytosolic levels of HDAC
activity in MRL/lpr 20 week-old mice compared to controls, while the
nuclear fraction showed elevated HDAC activity, which reached
Fig. 1Please check the presentation of this ﬁgure captions if correct and amend if necessary. HDAC6, 9, and 10 expression in immune cells from 12- and 20-week-old lupus and non-
lupusmice. Real-time RT-PCRwas used to determine expression of HDACs 6, 9, and 10 in B cells, T cells, and glomerular cells from lupus and controlmice. (A and C) BMB and splenic T cells
from MRL/lpr mice had signiﬁcantly higher expression of HDAC6 and HDAC9, and signiﬁcantly decreased HDAC10 expression compared to age-matched, healthy C57BL/6 mice.
(B) Expression ofHDAC6 andHDAC10were signiﬁcantly higher in B cells isolated from the spleens ofMRL/lprmice. (D) Glomerular cells from the lupus-pronemice had increased expres-
sion of HDACs 6 and 9, but no signiﬁcant differences in the expression of HDAC10 were noted (n ≥ 6; *p b 0.05, **p b 0.01).
497N.L. Regna et al. / International Immunopharmacology 29 (2015) 494–503statistical signiﬁcance in late-diseased mice (Fig. 2A). B cells from the
spleen of both early- and late-diseased MRL/lpr mice had signiﬁcantly
increased levels of both cytoplasmic and nuclear HDAC activity when
compared to age-matched controls at 20 weeks-of-age, with nuclear
HDAC activity showing the greatest differences (Fig. 2B).
Targeting of different HDAC isoforms, including HDAC6 and HDAC9,
has been demonstrated to increase Treg cell function through a number
of different mechanisms [13,31]. We isolated CD4+CD25+ cells and
CD4+CD25− T cells from the spleens of MRL/lpr and C57BL/6 mice
and evaluated the level of HDAC activity to determine associations be-
tween SLE disease and Treg HDAC activity. We found that CD4+CD25+
cells had more HDAC activity than CD4+CD25− T cells regardless
of mouse strain or age (Fig. 2C). Additionally, CD4+CD25+ cell HDAC
activity was signiﬁcantly greater in the MRL/lpr mice compared to
age-matched healthy control mice. Similar to the HDAC activity in B
cells, CD4+CD25+ cells had greater nuclear HDAC activity; however,
we also found an increase in the cytoplasmic HDAC activity.
Furthermore, signiﬁcantly elevated HDAC activity was found in glomer-
ular cells from MRL/lpr mice in cytoplasmic and nuclear fractions of
early- and late-disease animals compared to age-matched controls
(Fig. 2D).
3.3. HDAC6 activity is increased in diseased MRL/lpr mice
Because our results show elevated HDAC expression in BM B cells,
splenic T cells, and glomerular cells fromMRL/lprmice, we sought to de-
termine whether there was a speciﬁc increase in HDAC6 activity in
these mice. In order to determine the level of HDAC6 activity, HDAC6
protein was immunoprecipitated from nuclear and cytoplasmic frac-
tions isolated from B, T, and glomerular cells, then subjected to the
HDAC activity assay. We found that HDAC6 activity was primarily cyto-
plasmic; however, some HDAC6 nuclear activity was present in isolated
B, T, and glomerular cells (Fig. 3). HDAC6 activity was signiﬁcantly
higher in the cytoplasm in MRL/lpr mice compared to C57BL/6 mice.Furthermore, B, T, and glomerular cells isolated from 20-week-old
MRL/lpr mice had signiﬁcantly higher HDAC6 activity than 12-week-
old MRL/lpr mice indicating an association between HDAC6 activity
and disease progression (Fig. 3A–D).3.4. HDAC6 inhibition increases α-tubulin acetylation and decreases
cytoplasmic HDAC activity in B, T, and glomerular cells
Following HDAC6 inhibition, α-tubulin becomes acetylated [36].
Furthermore, Histone H3 becomes hyperacetylated following inhibition
of class I HDACs [37]. In order to determine the concentration at which
ACY-738 selectively inhibits HDAC6 without inhibiting class I HDACs,
mesangial cells were cultured and treated with increasing concentra-
tions of ACY-738 for 24 h, followed by Western blot analysis to deter-
mine α-tubulin and histone H3 acetylation levels. We found that ACY-
738 at 5 nM was able to signiﬁcantly increase the level of α-tubulin
acetylation while having little to no effect on acetylation of histone H3
(Fig. 4A).
In order to assess the ability of a selectiveHDAC6i (ACY-738) to inhibit
nuclear and cytoplasmicHDACactivity, isolated BMBcells, splenic B andT
cells, and glomerular cells were treated with either Trichostatin A (TsA, a
class I and II HDACi) or ACY-738. As previously discussed, a 5 nM concen-
tration of ACY-738 was selected for use in these experiments as ACY-738
increases α-tubulin acetylation without increasing acetylation of histone
H3. For TsA, we selected to use a 1 μMconcentration for use in these stud-
ies based on previously publishedwork indicating inhibition of class I and
II HDACs at this concentration [38]. Not surprisingly, we found that ACY-
738 (5 nM) had a greater inhibitory effect on the cytoplasmic fractions
compared to nuclear fractions from isolated B, T, and glomerular cells.
The ability of ACY-738 to inhibit HDAC activity was not dependent upon
the age or strain of mouse or on the cell type. TsA (1 μM) was able to in-
hibitHDACactivity in both cytoplasmic andnuclear fractions regardless of
mouse strain or age (Fig. 4B–E).
Fig. 2.HDAC activity is increased in B, T, and glomerular cells in 12- and 20-week-old lupusmice compared to non-lupus controls. AnHDAC activity assaywas used to assess HDAC activity
in B cells, T cells, and glomerular cells from lupus and control mice. (A) In B cells isolated from the BMof 20-week-oldMRL/lprmice, therewas a signiﬁcant increase in nuclear cytoplasmic
HDAC activity when compared to C57BL/6mice; however, therewas no signiﬁcant difference in the level of cytoplasmic activity at 12weeks-of-age. (B) The level of both cytoplasmic and
nuclear HDACactivitywas signiﬁcantly increased in splenic B cells from lupus-pronemice at 20weeks-of-agewhen compared to healthy, age-matched controls. (C) Treg cells isolated from
the spleens of MRL/lpr mice had signiﬁcantly higher nuclear and cytoplasmic HDAC activity at 20weeks-of-age compared to age-matched controls. Treg HDAC activity did not change de-
spite to further progression of disease in MRL/lpr mice. (D) Both cytoplasmic and nuclear HDAC activity was increased in glomerular cells from SLE mice. As the mice aged from 12 to 20
weeks-of-age and diseased progressed, cytoplasmic HDAC activity continued to increase in glomerular cells from MRL/lpr mice (n ≥ 6; *p b 0.05, **p b 0.01, ***p b 0.001).
498 N.L. Regna et al. / International Immunopharmacology 29 (2015) 494–5033.5. In vitro inhibition of HDAC6 in mesangial cells results in inhibition of
Hsp90 and a decrease in NF-κB nuclear translocation
Hyperacetylation of Hsp90 results in a decrease in Hsp90 function by
limiting its chaperone activity. Hsp90 activity is required for the proper
folding of a number of client proteins, including IKK, a key component
of the IκB signaling pathway and NF-κB nuclear translocation.
Lack of Hsp90 activity results in misfolded IKK and its subsequent
degradation, thereby, preventing NF-κB nuclear translocation [25,39].
Sera levels of Hsp90 have been proven to be elevated in SLE patients
and approximately 50% of patients generate anti-Hsp90 autoantibodies.
Some SLE patients have glomerular deposits of Hsp90 and elevated
Hsp90 levels have been correlated to IL-6 production and severity
of glomerulonephritis [30]. Mesangial cells are the primary resident
immunoregulatory cells found in the glomerulus and act to maintain
proper glomerular ﬁltration [40]. Our study showed that treatment
of mesangial cells with ACY-738 resulted in a slight, but not signiﬁ-
cant, increase in Hsp90 acetylation and decrease of non-acetylated
Hsp90 (Fig. 5A). HDAC6 inhibition also resulted in a decrease in
iNOS protein (Fig. 5A and B), which previous studies have shown to
be upregulated in the kidneys of SLE patients and mice with active
disease [41,42].
During SLE, NF-κB regulates both B and T cell development as well
as T cell activation. NF-κB controls the immune response throughregulation of inﬂammatory cytokine gene expression. During SLE,
increased nuclear translocation of NF-κB leads to increased iNOS
and IL-6 production and a pro-inﬂammatory environment in the
mesangium [43]. Our results showed that nuclear levels increased in a
time-dependent manner from 0 to 60 mins; however, treatment with
ACY-738 reduced nuclear levels of NF-κB in cultured mesangial cells
(Fig. 5C).
3.6. In vitro inhibition of HDAC6 in BM pre-B cells results in a pro-apoptotic
environment
During lymphopoiesis, B cells in the BM pass through two main
stages: pro-B and pre-B. Previous research has shown that B cell devel-
opment during the pre-B phase is dysregulated in lupus-prone mice
[44]. The pre-B cell dysregulation correlated to SLE disease activity and
was corrected following treatment with the selective HDAC6i, ACY-
738. Pre-B cells were cultured using the Methocult assay and CFUs
were counted. Treatment of pre-B cells with ACY-738 reduced the aver-
age number of CFUs formed after 7 days of culture (Fig. 6A). Cells were
collected and subjected to Western blot analysis for evaluation of
apoptosis-associated Bax and Bcl-2 proteins. Treatment of ACY-738 in-
creased the level of Bax, without altering Bcl-2 expression (Fig. 6B).
Bax expression is known to promote apoptosis, while Bcl-2 is a known
inhibitor of apoptosis.
Fig. 3. HDAC6 activity is increased in the cytoplasm from BM and splenic B cells, splenic T cells and glomerular cells in 12- and 20-week-oldMRL/lprmice compared to C57BL/6 controls.
HDAC6was immunoprecipitated from isolated B, T, and glomerular cells and subjected to an HDAC activity assay. (A) There were no signiﬁcant differences in nuclear HDAC6 activity in B
cells isolated from the BMofMRL/lpr and C57BL/6mice. (B) Splenic B cells had signiﬁcantly higher cytoplasmic HDAC6 activity from lupus-pronemice at 20weeks-of-age. Therewere no
signiﬁcant differences in the cytoplasmic HDAC6 activity at 12 weeks-of-age or in the nuclear HDAC activity. (C) Treg cells and (D) glomerular cells isolated from MRL/lpr mice exhibited
increased cytoplasmicHDAC6 activity regardless of age. HDAC6 activity continued to increase in glomerular cells as disease progressed in the lupus-pronemice (n ≥ 6; *p b 0.05, **p b 0.01).
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We found that the expression and activity of class II HDACs (6 and
9)were upregulated in early- and late-diseasedMRL/lprmice compared
to age-matched C57BL/6 control mice. On the other hand, HDAC10
was decreased in MRL/lpr mice compared to age-matched C57BL/6
animals in BM B cells and splenic T cells, but not in glomerular cells.
Furthermore, both nuclear and cytoplasmic HDAC activity was in-
creased in BM B cells, splenic B and T cells, and glomerular cells.
HDAC6 activity was found to be primarily cytoplasmic and most signif-
icantly increased in 20-week-oldMRL/lprmice. Treatmentwith the spe-
ciﬁc HDAC6i, ACY-738 (5 nM), was found to primarily decrease
cytoplasmic HDAC activity, whereas treatment with TsA (1 μM) de-
creased both nuclear and cytoplasmic HDAC activity. Inhibition of
HDAC6 in mesangial cells led to an increase in acetylated Hsp90 as
well as a decrease in nuclear levels of NF-κB. ACY-738was able to inhibit
pre-B cell proliferation through increased Bax expression in vitro. Taken
together these results suggest that HDAC6 inhibition is able to decrease
cytoplasmic HDAC activity through regulation of NF-κB and Hsp90 in
glomerular cells and through regulation of the Bcl-2:Bax ratio in pre-B
cells from the BM.
To date there have been relatively few studies on the role of
HDAC10 and its expression during disease. HDAC10 is a class IIb
HDAC that resides in both the nucleus and the cytoplasm [45].
The role of HDAC10 in the cytoplasm remains to be determined;
however, it has been shown to be a transcriptional modulator in
the nucleus [46]. HDAC10 expression was downregulated in BM B
and T cells in MRL/lpr mice compared to controls. However,HDAC10 expression was not altered with respect to the increased
disease activity suggesting that HDAC10 may not be a major factor
in SLE disease.
We have previously published that HDAC9-deﬁcient MRL/lpr mice
have decreased disease activity suggesting a role for HDAC9 in SLE path-
ogenesis [21]. HDAC9has been implicated in the regulation and the sup-
pressive function of Treg cells [31]. Our study showed that HDAC9 was
signiﬁcantly overexpressed in splenic T cells in MRL/lpr mice
compared to C57BL/6 mice. Due to the aberrant T cell development
associated with SLE, we examined HDAC activity in splenic T cells.
Speciﬁcally, we compared the HDAC activity of CD4+CD25− T cells
and CD4+CD25+ cells, which have decreased immunosuppressive
function in SLE patients and murine models of disease [47]. We
found CD4+CD25+ cells had increased HDAC activity regardless of the
strain or age of the mouse when compared to CD4+CD25− T cells.
HDAC9 is thought to inhibit Foxp3 function and that the nuclear
export of HDAC9 is required for optimal Treg suppressive function [14].
Once bound to Foxp3, HDAC9 decreases acetylation levels of Foxp3
resulting in increased polyubiquitination, proteasomal degradation,
and therefore decreased Foxp3 stability and function [48]. Overexpres-
sion of HDAC9 by splenic T cells may contribute to the decrease in Treg
cell number and function associated with MRL/lpr mice [49]. In
our studies, HDAC activity in CD4+CD25+ cells from lupus-prone
mice was found to be both nuclear and cytoplasmic, suggesting a
role for HDACs that are both nuclear and cytoplasmic in nature in
regards to regulation of these cells. It is important to note we used
CD4+CD25+ as a surrogate marker for Treg cells. In order for these
cells to be phenotyped as Tregs, Foxp3 must be expressed as reports
Fig. 4. ACY-738 treatment increased α-tubulin acetylation and HDAC activity is decreased with selective HDAC6 inhibition while cytoplasmic and nuclear activity is decreased following
pan-HDACi therapy. (A) Treatment ofmesangial cellswith ACY-738 increasedα-tubulin acetylation in a concentration dependentmanner. At the 5 nMconcentration, ACY-738was able to
increase α-tubulin acetylation without signiﬁcantly increasing the acetylation of the H3 histone. (B–E) Isolated cells were treated with class I and II HDACi, TsA, or the HDAC6 selective
inhibitor, ACY-738 for 24 h. ACY-738 (5 nM) was able to decrease cytoplasmic HDAC activity in BM B cells, splenic B and T cells, and glomerular cells. Treatment with TsA (1 μM) was
able to signiﬁcantly decrease both nuclear and cytoplasmic HDAC activity in both MRL/lpr and C57BL/6 mice (n ≥ 6; *p b 0.05, **p b 0.01, ***p b 0.001).
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MRL/lpr mice [50].
HDAC6 is a class IIb HDAC with a structure similar to HDAC9;
however, HDAC6 primarily resides in the cytoplasm. Substrates of
HDAC6 include α-tubulin and Hsp90, which become deacetylated
when HDAC6 catalyzes the removal of acetyl groups [25,30]. We in-
vestigated the level of HDAC6 expression in immune cells isolated
from early- and late-disease lupus-prone mice due to the role of
HDAC6 in cell development and regulation of gene transcription.
Studies with HDAC6 KO mice have shown a role for HDAC6 in T cell
survival and activation, speciﬁcally as a negative regulator of Tregs
[15]. We found that HDAC6 was overexpressed in BM B cells, splenic
B and T cells, and glomerular cells from diseased MRL/lpr mice. Fur-
thermore, when HDAC6 was isolated from these immune cells, we
found that HDAC6 activity was increased in both B and T cells from
diseased lupus mice. These results suggest that HDAC6 may play arole in the dysregulation of both B and T cell development during
SLE.
Since HDAC6 was overexpressed in all of the immune cells isolated
from MRL/lpr mice, we tested whether a speciﬁc HDAC6i would be
able to decrease HDAC activity in vitro. At a 5 nM concentration, ACY-
738 signiﬁcantly increased α-tubulin acetylation without signiﬁcantly
altering acetylation of histone H3. Furthermore, B, T, and glomerular
cells treated with ACY-738 had signiﬁcantly decreased cytoplasmic
HDAC activity while having no signiﬁcant effect on nuclear HDAC activ-
ity. These results suggest that ACY-738 is selective for HDAC6 over class
I HDACs at a 5 nM concentration.
Glomerulonephritis is the leading cause of morbidity and mortality
in SLE patients [51,52].We found thatHDAC6was overexpressed in glo-
merular cells from diseased MRL/lpr mice. Furthermore, isolated glo-
merular cells from MRL/lpr mice had a cytoplasmic increase in HDAC
activity. Since HDAC6 is found in the cytoplasm, these results suggest
Fig. 5. HDAC6 inhibition alters mesangial cell protein expression in vitro. (A–B)Western blot analysis showing a decrease in iNOS and Hsp90 protein levels in mesangial cells stimulated
with LPS/IFN-γ for 24 h following treatmentwith ACY-738. (C) ACY-738 (5 nM) treatmentwas also able to decrease nuclear levels of NF-κB following LPS/IFN-γ-stimulation of mesangial
cells in a time dependent manner. All experiments were run in triplicate (n ≥ 3; *p b 0.05).
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vitro immune stimulation of mesangial cells by LPS/IFN-γ led to in-
creased activation of NF-κB in a time-dependentmanner. HDAC6 inhibi-
tion by ACY-738 (5 nM) was found to decrease nuclear translocation of
NF-κB in immune-stimulated mesangial cells. When NF-κB is activated,
it is translocated into the nucleus allowing for gene regulation [53]. We
also found that HDAC6 inhibition decreased Hsp90 in a concentration-
dependent manner in cultured mesangial cells. Increased Hsp90
acetylation results in inhibition of Hsp90 chaperone function and
proteosomal degradation of Hsp90 client proteins [24]. Furthermore,
Hsp90 plays a role in activation of lymphocytes and antigen presenta-
tion and has been demonstrated to be elevated in the serum from SLE
patients. During SLE, elevated Hsp90 levels have been correlated to IL-
6 and autoantibody production suggesting that Hsp90 may contribute
to disease progression [30]. Hsp90 plays a key role in the induction of
iNOS and is required for transcriptional factor binding to iNOS pro-
moters. NF-κB is a known inducer of iNOS and when Hsp90 is inhibited
there is a subsequent reduction in the ability of NF-κB to induce iNOS
expression [54].Wehave found that pre-B cell development is dysregulated in lupus-
pronemice (unpublished data). When pre-B cells were cultured from a
single-cell suspension isolated from the BM, treatment with ACY-738
inhibited the formation of pre-B cell CFUs. Furthermore, treatment
with this selective HDAC6i increased the pro-apoptotic protein, Bax,
without altering expression of the apoptosis inhibitor, Bcl-2. During
SLE the ratio of Bcl-2:Bax has been shown to be increased in lympho-
cytes suggesting a role of decreased apoptosis in SLE pathogenesis
[55]. The elevated ratio of Bcl-2:Bax in lymphocytes from SLE patients
is believed to contribute to the survival of autoreactive B cells that pro-
duce pathogenic autoantibodies [56]. The ability of HDAC6 inhibition to
decrease the ratio of Bcl-2:Bax in pre-B cellsmay help to increase the re-
moval of autoreactive B cells during active SLE.
Altered histone acetylation has recently been implicated in the path-
ogenesis of a number of diseases including cancer, cardiac hypertrophy,
diabetes, and multiple sclerosis [57–59]. Studies have suggested that
treatment of SLE with HDAC inhibitors may be able to correct aberrant
B and T cell development [60]. SLE is a chronic autoimmune disease re-
quiring long-term treatment [61]. Use of pan-HDAC inhibitors may not
Fig. 6. Apoptotic markers are increased in pre-B cells following treatment with ACY-738. Pre-B cells were cultured using aMethocult assay in the presence or absence of IL-7 and ACY-738.
(A) ACY-738 inhibited the growth of pre-B cells in vitrowhen treatedwith IL-7. (B) Cultured pre-B cells subjected toWestern blot analysis were found to have increased Bax proteinwith
increasing concentrations of ACY-738. (C) The Bcl-2:Bax ratiowas determined using densitometric analysis. Treatmentwith ACY-738 decreased the Bcl-2:Bax ratio in cultured pre-B cells.
All experiments were run in triplicate (n ≥ 6; *p b 0.05, **p b 0.01, ***p b 0.001).
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treatment, therefore the development of isoform-selective HDAC inhib-
itors for the treatment of lupus to speciﬁcally target abnormal immune
cells is preferred [16,62]. Our results suggest that overexpression of
HDACmRNA and HDAC activity in B, T, and glomerular cells contributes
to disease in MRL/lpr lupus-prone mice. We found that HDAC6 inhibi-
tion by ACY-738 is able to inhibit NF-κB nuclear translocation. Taken to-
gether these data suggest that inhibition of speciﬁc HDAC isoformsmay
be beneﬁcial in the treatment of SLE and that further studies are war-
ranted to determine their efﬁcacy.
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